Science AI Journal
Medicine · Research topic

Open research questions in Myasthenia Gravis and Thymoma

61 unresolved questions extracted from the limitations and future-work sections of 150 Myasthenia Gravis and Thymoma papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Evaluating LN metastasis in TETs using CT imaging is challenging due to the lack of standardized criteria. The small number of patients with pathologically confirmed LN metastasis limits the interpretation of the findings.

    Could Pretreatment Computed Tomography Imaging Accurately Predict the Pathological Diagnosis of Lymph Node Involvement in Thymic Epithelial Tumors? · 2026 · DOI

  • Further studies are needed to validate the findings of this study. Future research should investigate the development of standardized CT criteria for evaluating LN metastasis in TETs.

    Could Pretreatment Computed Tomography Imaging Accurately Predict the Pathological Diagnosis of Lymph Node Involvement in Thymic Epithelial Tumors? · 2026 · DOI

  • The rare occurrence of bronchogenic cysts in the chest wall. The potential risks of infection, compression, enlargement, and even rare malignant transformation. The need for comprehensive evaluation of long-standing masses that undergo change.

    Case Report: A seventy-year-stable chest wall bronchogenic cyst with sudden enlargement: coincidence or connection with a concurrent thymic carcinoma? · 2026 · DOI

  • Limited understanding of the pathophysiology of generalized myasthenia gravis. Difficulty in achieving satisfactory symptomatic control with conventional immunosuppressive therapies. Potential side effects associated with long-term steroid use.

    Real-world study of efgartigimod in AChR antibody-positive generalized myasthenia gravis: thymus status, multi-domain symptom improvement and steroid-sparing effect · 2026 · DOI

  • Limited real-world evidence for the efficacy of efgartigimod in treating generalized myasthenia gravis. Limited understanding of the steroid-sparing effect of efgartigimod. Limited understanding of the impact of thymus status on the response to efgartigimod.

    Real-world study of efgartigimod in AChR antibody-positive generalized myasthenia gravis: thymus status, multi-domain symptom improvement and steroid-sparing effect · 2026 · DOI

  • The risk of antibody overshoot following efgartigimod treatment. The lack of adequate immunosuppressive therapy prior to efgartigimod initiation. The need for regular monitoring of anti-AChR antibody levels during efgartigimod treatment.

    Anti-acetylcholine receptor antibody overshoot following efgartigimod in myasthenia gravis: Two case reports with literature review · 2026 · DOI

  • The risk factors and optimal management of antibody overshoot remain inadequately characterized. There is a lack of studies on the incidence and management of antibody overshoot following efgartigimod treatment.

    Anti-acetylcholine receptor antibody overshoot following efgartigimod in myasthenia gravis: Two case reports with literature review · 2026 · DOI

  • The overlap of ocular myasthenia gravis with other common eye or nerve disorders. The limitations of current diagnostic methods, with no single test able to definitively diagnose myasthenia gravis. The need for more focused research on ocular forms of MG to address the biological complexity of the disease.

    Ocular Myasthenia Gravis: Diagnosis, Management, and Risk of Disease Progression · 2026 · DOI

  • Diagnosing ectopic thymomas can be challenging due to their rare location. Treating refractory MG can be difficult due to the lack of response to conventional therapies.

    An Exceptional Preaortic Ectopic Type B2 Thymoma as the Cause of Refractory Myasthenia Gravis: A Case Report · 2026 · DOI

  • The high cost and logistical constraints of echocardiography, PET/CT, and micro-CT acquisition limited the imaging subset size. The study required a multi-dimensional phenotyping framework to investigate the complex relationships between neuromuscular dysfunction, immune alterations, and whole-animal phenotypic changes.

    A multi-dimensional phenotyping framework reveals coordinated neuromuscular, immune, and imaging-derived phenotypes in experimental autoimmune myasthenia gravis · 2026 · DOI

  • The underlying mechanism of delayed growth in bronchogenic cysts is not well understood. The potential pathological interaction between bronchogenic cysts and thymic carcinomas is not well recognized.

    Case Report: A seventy-year-stable chest wall bronchogenic cyst with sudden enlargement: coincidence or connection with a concurrent thymic carcinoma? · 2026 · DOI

  • However, there are limited data on the accuracy of the different methods available for acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) autoantibody (Ab) detection in a real-world setting.

    Accuracy of Antibody Testing in Myasthenia Gravis · 2026 · DOI

  • Findings are limited by the absence of a control arm, which precludes definitive attribution of clinical improvement to efgartigimod alone.

    Prospective study of efgartigimod in severe myasthenia gravis exacerbations requiring ventilatory or enteral support · 2026 · DOI

  • No biomarkers currently exist to identify patients at risk for highly active disease course. There is a need to identify blood-based biomarker signatures associated with a highly active disease course in immunotherapy-naïve patients with acetylcholine-receptor-antibody positive generalized Myasthenia gravis.

    Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocol · 2026 · DOI

  • The study is exploratory, and the number of cases is not sufficient to answer confirmatory questions. The study only serves to discover indications of possible correla- tions between biomarker levels and outcomes. Overall patient sample size is estimated based on a 10-15% of gMG patients progressing to a highly active disease course within PROGNO-MG will provide important, prospective clinical data on AChR+ gMG with highly active disease course and allow the evaluation of proposed biomarkers (calprotectin, neurofilament light chain, ITIH3, complement activation, kappa free light chains) in a well-defined immunotherapy- naïve gMG subset. It will further evaluate temporal immune 1 3Neurological Research and Practice (2026) 8:38 cell phenotypes and proteomic profiles of these patients. Early identification of patients at risk for a highly active dis- ease course may enable targeted therapeutic approaches to improve patient outcomes and reduce disease burden. Acknowledgements The authors thank our co-worker Norbert Baro of the Neuroscience Clinical Research Center for patient management as well as Sandra Lischewski and Marret Heinold for administration support. Author contributions F.S., A.M., and H.W. conceptualized and de- signed the study. F.K., F.F.K. and F.S. wrote the manuscript. All au- thors revised the manuscript for intellectual content. Funding Open Access funding enabled and organized by Projekt DEAL. https:/ /doi.or g/10.13 039/1 00006396. Alexion P h a r m a c e u t i c a l s . Data availability Anonymized study data will be available upon rea- sonable request following publication of the study results.

    Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocol · 2026 · DOI

  • Further studies are needed to improve the diagnosis and management of ITTC. Research on the molecular mechanisms underlying ITTC is necessary to develop targeted therapies.

    Intrathyroidal Thymic Carcinoma With Extra-Thyroid Invasion and Lymph Nodal Metastasis: Two Case Reports and Literature Review · 2026 · DOI

  • ITTC poses diagnostic challenges due to its resemblance to poorly differentiated or anaplastic thyroid carcinoma. There is a lack of awareness and understanding of ITTC among clinicians and pathologists.

    Intrathyroidal Thymic Carcinoma With Extra-Thyroid Invasion and Lymph Nodal Metastasis: Two Case Reports and Literature Review · 2026 · DOI

  • There is a lack of awareness of superior herniation of the thymus among clinicians. The condition often leads to unnecessary investigations and interventions.

    Now you see it; Now you don't: Superior herniation of thymus presenting as an intermittent anterior neck mass · 2026 · DOI

  • There is a need to identify factors associated with secondary generalization in patients with ocular-onset myasthenia gravis. There is a lack of understanding of the clinical relevance of quantitative anti-AChR antibody assessment for risk stratification in ocular-onset myasthenia gravis.

    Risk factors for disease generalization in acetylcholine receptor antibody-positive ocular myasthenia: a multicenter retrospective study · 2026 · DOI

  • The study identifies a gap in the literature comparing different robotic platforms and VATS in thymectomy. The study highlights the need for further research on the learning curves and surgeon workload associated with each technique.

    Minimally invasive thymectomy: comparative analysis of short-term outcomes after video-assisted thoracoscopy and two robotic platforms · 2026 · DOI

  • The lack of large prospective studies and randomized trials due to the rarity of thymoma. The need for contemporary population-level data to define thymoma epidemiology and prognosis.

    Thymoma in the United States (2000-2023): Population-Based Incidence, Treatment Patterns, and Survival · 2026 · DOI

  • More focused research on ocular forms of MG is needed to address the biological complexity of the disease. Research on new diagnostic methods and therapeutic strategies is necessary to improve patient outcomes.

    Ocular Myasthenia Gravis: Diagnosis, Management, and Risk of Disease Progression · 2026 · DOI

  • High-quality clinical evidence in juvenile gMG remains scarce. There is an urgent need for novel therapeutic alternatives for pediatric patients with gMG.

    Telitacicept in refractory juvenile generalized myasthenia gravis: a case report and collective analysis · 2026 · DOI

  • 2,4 e pathophysiological mechanism of DPA–induced MG remains incompletely understood. is a well-described but frequently DPA–induced MG underrecognized adverse effect, particularly in patients treated for Wilson’s disease.

    A rare case of D-penicillamine induced Myasthenia Gravis · 2026 · DOI

  • There is a need for more effective treatments for myasthenia gravis. Real-world evidence on the efficacy and safety of eculizumab in this patient population is limited.

    Eculizumab in Myasthenia Gravis: A Multicenter Retrospective Real-World Study in China · 2026 · DOI

Most-cited papers in Myasthenia Gravis and Thymoma

Most recent work

Find a gap in your own Myasthenia Gravis and Thymoma sub-topic

This page shows what the Myasthenia Gravis and Thymoma literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
1,213 open questions
Artificial Intelligence in Healthcare and Education
1,153 open questions
Physical Activity and Health
718 open questions
Dementia and Cognitive Impairment Research
565 open questions
Attention Deficit Hyperactivity Disorder
544 open questions
Smoking Behavior and Cessation
532 open questions
Innovations in Medical Education
480 open questions
HIV/AIDS Research and Interventions
472 open questions
61 open questions have been extracted from the limitations and future-work passages of 150 Myasthenia Gravis and Thymoma papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.